Vnitr Lek 2005, 51(2):153-156

Smíšená kryoglobulinemie jako extrahepatální manifestace infekce virem hepatitidy C - editorial

P. Urbánek
IV. interní klinika 1. lékařské fakulty UK a VFN, Praha, přednosta doc. MUDr. A. Žák, DrSc.

Received: April 18, 2004; Published: February 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Urbánek P. Smíšená kryoglobulinemie jako extrahepatální manifestace infekce virem hepatitidy C - editorial. Vnitr Lek. 2005;51(2):153-156.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kunkel HG, Agnello V, Joslin FG et al. Cross-idiotypic specificity among monoclonal IgM proteins with Anti-gama globulin activity. J Exp Med 1973; 137: 331-342. Go to original source... Go to PubMed...
    2. Agnello V, Zhang QX, Abel G et al. The association of hepatitis C virus infection with monoclonal rheumatoid factors bearing the WA crossidiotype: implications for the etiopahogenesis and therapy of mixed cryoglobulinemia. Clin Exp Rheum 1995; 13: 5101-5104.
    3. Agnello V, Abel G, Knight GB et al. The role of hepatitis C virus in the pathogenesis of type II cryoglobulinemia. Hepatitis C and Beyond. Keystone Symposia, Burlington, VT 1995: 8, abstract 007.
    4. Akriviadis EA, Xanthakis I, Navrozidou C et al. Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-alfa. J Clin Gastroenterol 1997; 25: 612-618. Go to original source... Go to PubMed...
    5. Donada C, Crucitti A, Donadon V et al. Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia. J Viral Hepat 1998; 3: 179-185. Go to original source... Go to PubMed...
    6. EASL International Consensus Conference on Hepatitis C. J Hepatol 1999; 30: 956-961. Go to PubMed...
    7. Ferri C, Marzo M, Longombardo G et al. Interferon alfa in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993; 81: 1132-1136. Go to original source...
    8. Misiani R, Bellavita P, Fenilli D et al. Interferon-alfa 2a therapy in cryoglobulinemia assciated with hepatitis C virus. N Engl J Med 1994; 330: 751-756. Go to original source... Go to PubMed...
    9. Casato M, Lagana B, Antonelli B et al. Long-term results of therapy with interferon-alfa for type II essential mixed cryoglobulinemia. Blood 1991; 78: 3142-3147. Go to original source...
    10. Casato M, Agnello V, Pucillo P et al. Predictors of long-term response to hig-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997; 90: 3865-3875. Go to original source...
    11. Della Rossa A, Taveni A, Baldini C et al. Treatment of chronic hepatitis C infection with cryoglobulinemia. Curr Opin Rheumatol 2002; 14: 231-237. Go to original source... Go to PubMed...
    12. Mazzaro C, Zorat F, Comar C et al. Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. J Rheumatol 2003; 30: 1775-1781. Go to PubMed...
    13. Tarantino A et al. Long term predictors of survival in essentialle mixed cryoglobulinemic glomerulonefritis. Kidney Intern 1995; 47: 618-623. Go to original source... Go to PubMed...
    14. Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-3834. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.